
PARTNERSHIPS
10 Mar 2026
Roche secures global rights to MediLink’s YL201 ADC, expanding its oncology pipeline and deepening cross-border biotech partnerships

INNOVATION
20 Feb 2026
Taiho’s Araris deal highlights linker chemistry as a critical edge in building safer, more consistent antibody drug conjugates

REGULATORY
12 Feb 2026
Draft guidance elevates MRD and complete response, clearing a faster regulatory path for new multiple myeloma therapies

INVESTMENT
9 Feb 2026
Solve Therapeutics raises $120M with backing from MSD and others, betting that smarter ADC design can finally unlock solid tumors

TECHNOLOGY
4 Feb 2026
AI is reshaping antibody drug design as pharma turns to early partnerships to cut risk, speed timelines, and stay competitive

INSIGHTS
24 Jan 2026
AbbVie’s RC148 deal with RemeGen reflects a broader push to combine ADCs with complementary drugs for longer lasting cancer responses
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.